New drug combo tested for Tough-to-Treat rare cancers
NCT ID NCT02938793
Summary
This study tested a combination of two immunotherapy drugs, durvalumab and tremelimumab, for people with advanced rare solid tumors who had no other standard treatment options. The goal was to see if the drugs could shrink tumors and were safe for patients. The trial was designed for a specific group of rare cancers and required participants to have tissue samples available for testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Greenville Health System Cancer Institute
Greenville, South Carolina, 29605, United States
Conditions
Explore the condition pages connected to this study.